Compare Biogen Inc (BIIB) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Oklo Inc — how do they compare? Biogen Inc trades at $190.6 (market cap $28.34B), while Oklo Inc trades at $46.29 (market cap $8.05B). The key difference: Biogen Inc is far larger — about 3.5× Oklo Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | OKLO | |
|---|---|---|
Market Cap | $28.34B | $8.05B |
Sector | Health | Technology |
52-Week High | $216.63 | $174.14 |
52-Week Low | $122.68 | $45.58 |
Enterprise Value | $30.62B | $5.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
OKLO stock trades at $45.81, down 6.22% in the last session, reflecting ongoing volatility. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but faces fundamental challenges with negative ROE (-8.87%) and net income (-$105.66M). Recent DOE approval for the Groves Isotope Test Reactor represents a key regulatory milestone, though cash flow remains heavily dependent on financing activities.
The outlook balances significant growth potential in nuclear energy against substantial execution risks. While analyst targets suggest 98% upside, the company must navigate regulatory hurdles and achieve profitability amid negative earnings trends. The stock's bearish technical signals and high valuation multiples require careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
